Joshua Sabari, MD, is an assistant professor of medicine, thoracic medical oncology, Perlmutter Cancer Center NYU Langone Health.
Different Types of Biomarker Testing Methods Used in Patients with NSCLC
January 31st 2023Drs Socinski and Sabari explain the different types of testing methods commonly used in their clinical practice and share advice for community oncologists who are testing for biomarkers in their patients with NSCLC.
First-Line Treatment Paradigm of NSCLC and the Advent of Immunotherapy
December 7th 2022Joshua Sabari, MD, a thoracic medical oncologist at NYU Langone Health Perlmutter Cancer Center in New York, NY reviews clinical trial data and explains the rationale of using tumor-infiltrating lymphocytes (TILs) in non-small cell lung cancer (NSCLC) treatment.
A Historical Perspective on First-Line Treatment of NSCLC and Recent Advances in Immunotherapy
November 14th 2022In the first installment of this series, Joshua Sabari, MD, provides an overview on the use of chemotherapy for first-line treatment of NSCLC, and discusses how the more recent availability of PD-1/PD-L1– and CTLA-4–targeted immunotherapy is changing the field.